What is the difference between Type 1 Diabetes Mellitus (T1DM) and Latent Autoimmune Diabetes in Adults (LADA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Type 1 diabetes and latent autoimmune diabetes in adults (LADA) are distinct conditions with different progression rates and treatment approaches, with type 1 requiring immediate insulin therapy and LADA potentially starting with oral medications before transitioning to insulin. The key difference between the two conditions lies in their rate of progression and the age of onset. Type 1 diabetes typically develops rapidly in children or young adults, with sudden onset of symptoms like excessive thirst, frequent urination, and weight loss, requiring immediate insulin therapy for survival 1. In contrast, LADA progresses more slowly, usually appearing in adults over 30, and may initially resemble type 2 diabetes. People with LADA often maintain some insulin production for months or years after diagnosis, sometimes allowing them to manage with oral medications initially before eventually requiring insulin.

Some of the key characteristics of type 1 diabetes include:

  • Autoimmunity, with the presence of multiple islet autoantibodies
  • Normoglycemia or dysglycemia, with a rapid progression to overt hyperglycemia
  • Presymptomatic or symptomatic presentation
  • Diagnostic criteria based on the presence of autoantibodies, dysglycemia, and hyperglycemia
  • A high risk of developing symptomatic type 1 diabetes, with a 5-year risk of 44% overall, varying based on the number, titer, and specificity of autoantibodies, as well as age of seroconversion and genetic risk 1

In contrast, LADA is characterized by:

  • A more gradual autoimmune destruction of beta cells
  • A slower progression to overt hyperglycemia
  • The presence of antibodies like GAD (glutamic acid decarboxylase)
  • A potential initial response to oral medications, with a eventual transition to insulin therapy as beta cell function declines
  • A distinct clinical presentation, with adults over 30 often presenting with mild hyperglycemia, responsive to oral agents, but eventually developing more severe hyperglycemia and requiring intensive insulin regimens 1

The treatment approaches for type 1 diabetes and LADA differ based on their progression rates. Type 1 diabetes requires immediate insulin therapy, while LADA may start with oral medications but typically transitions to insulin therapy as beta cell function declines. Regular monitoring of blood glucose and antibody testing can help distinguish between these conditions when diagnosis is unclear. The most recent and highest quality study, published in 2025, provides guidance on the diagnosis and classification of diabetes, including the staging of type 1 diabetes and the characteristics of LADA 1.

From the Research

Difference between Type 1 Diabetes and Latent Autoimmune Diabetes

  • Type 1 diabetes is an autoimmune condition where the body's immune system attacks and destroys the insulin-producing beta cells in the pancreas, resulting in a lack of insulin production 2, 3, 4.
  • Latent autoimmune diabetes, on the other hand, is a form of type 1 diabetes that progresses slowly, often in adults, and is characterized by the presence of autoimmune antibodies against pancreatic islet cells, but with a slower destruction of beta cells 5, 6.
  • The main difference between the two conditions is the rate of progression and the age of onset, with type 1 diabetes typically occurring in children and adolescents, and latent autoimmune diabetes occurring in adults.
  • In terms of treatment, both conditions require insulin therapy, but the approach may differ, with type 1 diabetes often requiring multiple daily injections or insulin pump therapy, and latent autoimmune diabetes may be managed with oral medications or a single daily injection of insulin 2, 3, 4, 5, 6.
  • It's worth noting that the provided studies do not directly compare type 1 diabetes and latent autoimmune diabetes, but rather discuss the management and treatment of type 1 diabetes, highlighting the importance of insulin therapy and glycemic control in managing the condition 2, 3, 4, 5, 6.

Key Characteristics

  • Type 1 diabetes:
    • Autoimmune condition
    • Rapid progression
    • Typically occurs in children and adolescents
    • Requires insulin therapy
  • Latent autoimmune diabetes:
    • Autoimmune condition
    • Slow progression
    • Typically occurs in adults
    • May be managed with oral medications or insulin therapy

Treatment Approaches

  • Type 1 diabetes:
    • Multiple daily injections of insulin
    • Insulin pump therapy
    • Continuous glucose monitoring
  • Latent autoimmune diabetes:
    • Oral medications
    • Single daily injection of insulin
    • Lifestyle modifications (e.g. diet, exercise)

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin treatment in type 1 diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2006

Research

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020

Research

Contemporary management of patients with type 1 diabetes.

Endocrinology and metabolism clinics of North America, 2010

Research

Advances in newer basal and bolus insulins: impact on type 1 diabetes.

Current opinion in endocrinology, diabetes, and obesity, 2021

Research

Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.